CA3000792A1 - Means and methods for treating copper-related diseases - Google Patents

Means and methods for treating copper-related diseases Download PDF

Info

Publication number
CA3000792A1
CA3000792A1 CA3000792A CA3000792A CA3000792A1 CA 3000792 A1 CA3000792 A1 CA 3000792A1 CA 3000792 A CA3000792 A CA 3000792A CA 3000792 A CA3000792 A CA 3000792A CA 3000792 A1 CA3000792 A1 CA 3000792A1
Authority
CA
Canada
Prior art keywords
methanobactin
copper
treatment
binding
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3000792A
Other languages
English (en)
French (fr)
Inventor
Hans Zischka
Josef LICHTMANNEGGER
Alan Angelo Dispirito
Jeremy David Semrau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Iowa State University Research Foundation Inc ISURF
University of Michigan System
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Iowa State University Research Foundation Inc ISURF
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH, Iowa State University Research Foundation Inc ISURF, University of Michigan System filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Publication of CA3000792A1 publication Critical patent/CA3000792A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/30—Copper compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3000792A 2015-12-18 2016-12-16 Means and methods for treating copper-related diseases Pending CA3000792A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15201070.8 2015-12-18
EP15201070 2015-12-18
LU92979 2016-02-19
LU92979 2016-02-19
PCT/EP2016/081407 WO2017103094A2 (en) 2015-12-18 2016-12-16 Means and methods for treating copper-related diseases

Publications (1)

Publication Number Publication Date
CA3000792A1 true CA3000792A1 (en) 2017-06-22

Family

ID=57758583

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3000792A Pending CA3000792A1 (en) 2015-12-18 2016-12-16 Means and methods for treating copper-related diseases

Country Status (6)

Country Link
US (2) US11000568B2 (enExample)
EP (2) EP3389648A2 (enExample)
JP (1) JP7123339B2 (enExample)
CN (1) CN108472281B (enExample)
CA (1) CA3000792A1 (enExample)
WO (1) WO2017103094A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116333047A (zh) * 2022-12-22 2023-06-27 四川大学华西医院 一种抗菌肽及其制备方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3389648A2 (en) * 2015-12-18 2018-10-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating copper-related diseases
JP7145209B2 (ja) * 2017-06-14 2022-09-30 ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） ヒト胚性幹細胞から誘導された内胚葉及び膵内胚葉細胞を精製するための方法
CN109576226A (zh) * 2018-12-24 2019-04-05 博尔赛(上海)细胞生物技术有限公司 一种iPS细胞及其重编程方法和用途
CN109706099A (zh) * 2019-01-25 2019-05-03 黑龙江大学 同时去除低温地下水中有机磷农药和硝酸盐的假单胞菌及其应用
JPWO2021149824A1 (enExample) * 2020-01-24 2021-07-29
JP2022104813A (ja) 2020-12-29 2022-07-11 アイ ピース，インコーポレイテッド リプログラミング因子を導入された細胞の培養方法
US20240131112A1 (en) * 2021-02-01 2024-04-25 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Use of methanobactin for treatment of iron-related diseases
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199099B2 (en) * 2002-12-19 2007-04-03 The University Of Kansas Methanobactin: a copper binding compound having antibiotic and antioxidant activity isolated from methanotrophic bacteria
US7932052B1 (en) * 2006-07-24 2011-04-26 The Regents Of The University Of Michigan Use of methanobactin
EP3389648A2 (en) * 2015-12-18 2018-10-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Means and methods for treating copper-related diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116333047A (zh) * 2022-12-22 2023-06-27 四川大学华西医院 一种抗菌肽及其制备方法

Also Published As

Publication number Publication date
CN108472281B (zh) 2023-09-08
WO2017103094A3 (en) 2017-07-27
JP2018538306A (ja) 2018-12-27
CN108472281A (zh) 2018-08-31
US11000568B2 (en) 2021-05-11
EP4574207A3 (en) 2025-09-10
JP7123339B2 (ja) 2022-08-23
WO2017103094A2 (en) 2017-06-22
EP3389648A2 (en) 2018-10-24
US20190328835A1 (en) 2019-10-31
US20210369809A1 (en) 2021-12-02
EP4574207A2 (en) 2025-06-25

Similar Documents

Publication Publication Date Title
US20210369809A1 (en) Means and methods for treating copper-related diseases
Mori et al. Protein carbamylation exacerbates vascular calcification
Lichtmannegger et al. Methanobactin reverses acute liver failure in a rat model of Wilson disease
Glushchenko et al. Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease
US20230414709A1 (en) Mutant ngal proteins and uses thereof
Abplanalp et al. The cataract and glucosuria associated monocarboxylate transporter MCT12 is a new creatine transporter
US12173037B1 (en) Mutant NGAL proteins and uses thereof
Lindeque et al. The involvement of metallothioneins in mitochondrial function and disease
Brunet et al. Protein-bound uremic retention solutes
Antunes et al. Hepcidin: an important iron metabolism regulator in chronic kidney disease
US20210130291A1 (en) Methods for treating diabetes using vdac1 inhibitors
Qian et al. The involvement of copper transporter in lead-induced oxidative stress in astroglia
Li et al. Diet-induced hyperhomocysteinemia impairs vasodilation in 5/6-nephrectomized rats
US9770500B2 (en) S-nitrosylation of glucosylating toxins and uses therefor
Du et al. Inhibiting xCT/SLC7A11 induces ferroptosis of myofibroblastic hepatic stellate cells and protects against liver fibrosis
DiMartino et al. Activation of branched chain amino acid catabolism protects against nephrotoxic acute kidney injury
DK3020725T3 (en) PROCEDURE FOR PREPARING HYPO-METALLETED REDOX ACTIVE METALLOTHIONEIN PROTEIN AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
Opladen et al. Effect of antiepileptic drugs and reactive oxygen species on folate receptor 1 (FOLR1)-dependent 5-methyltetrahydrofolate transport
US20230165934A1 (en) Means and methods for treating copper-related diseases
Lu et al. Caffeic acid phenethyl ester protects renal tubular epithelial cells against ferroptosis in diabetic kidney disease via restoring PINK1-mediated mitophagy
Weber The Role of Compartmentalized Metabolism in Cellular Metal Homeostasis
Yi et al. Methionine restriction attenuates renal injury by suppressing macrophage polarization via IRF1 downregulation
Mosca Spermidine Protects Mitochondria Against Amyloid-β Oligomers
Shafer From Chlamydomonas reinhardtii to Caenorhabditis elegans: Investigations into the Environmental Regulation of Eukaryotic Cu-Handling Mechanisms
WO2022043265A1 (en) Compositions and methods comprising d-cysteine or a d-derivative thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201

EEER Examination request

Effective date: 20211201